Related references
Note: Only part of the references are listed.Design, synthesis, evaluation, and SAR of 4-phenylindoline derivatives, a novel class of small-molecule inhibitors of the programmed cell death-1/programmed cell death-ligand 1 (PD-1/PD-L1) interaction
Yang Yang et al.
EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY (2021)
Recent advance of peptide-based molecules and nonpeptidic small-molecules modulating PD-1/PD-L1 protein-protein interaction or targeting PD-L1 protein degradation
Chenghao Pan et al.
EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY (2021)
Progress in PD-1/PD-L1 pathway inhibitors: From biomacromolecules to small molecules
Xin Lin et al.
EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY (2020)
Discovery of the programmed cell death-1/programmed cell death-ligand 1 interaction inhibitors bearing an indoline scaffold
Mingze Qin et al.
EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY (2020)
New insight in endocrine-related adverse events associated to immune checkpoint blockade
Giusy Elia et al.
BEST PRACTICE & RESEARCH CLINICAL ENDOCRINOLOGY & METABOLISM (2020)
The yin and yang of co-inhibitory receptors: toward anti-tumor immunity without autoimmunity
Alexandra Schnell et al.
CELL RESEARCH (2020)
Flurbiprofen as a biphenyl scaffold for the design of small molecules binding to PD-L1 protein dimer
Christian Bailly et al.
BIOCHEMICAL PHARMACOLOGY (2020)
Design, synthesis and biological evaluation of 2-methyl-(1,1′-biphenyl)-pyrimidine conjugates
An Chen et al.
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS (2020)
Discovery of novel resorcinol diphenyl ether-based PROTAC-like molecules as dual inhibitors and degraders of PD-L1
Binbin Cheng et al.
EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY (2020)
Discovery of Novel Resorcinol Dibenzyl Ethers Targeting the Programmed Cell Death-1/Programmed Cell Death-Ligand 1 Interaction as Potential Anticancer Agents
Binbin Cheng et al.
JOURNAL OF MEDICINAL CHEMISTRY (2020)
Opportunities for Small Molecules in Cancer Immunotherapy
Sabina Y. van der Zanden et al.
TRENDS IN IMMUNOLOGY (2020)
Di-bromo-Based Small-Molecule Inhibitors of the PD-1/PD-L1 Immune Checkpoint
Magdalena Konieczny et al.
JOURNAL OF MEDICINAL CHEMISTRY (2020)
Synthesis and Evaluation of Biphenyl-1,2,3-Triazol-Benzonitrile Derivatives as PD-1/PD-L1 Inhibitors
Suresh Narva et al.
ACS OMEGA (2020)
Discovery of Novel and Highly Potent Resorcinol Dibenzyl Ether-Based PD-1/PD-L1 Inhibitors with Improved Drug-like and Pharmacokinetic Properties for Cancer Treatment
Binbin Cheng et al.
JOURNAL OF MEDICINAL CHEMISTRY (2020)
Recent Advances in the Development of PD-L1 Modulators: Degraders, Downregulators, and Covalent Inhibitors
Binbin Cheng et al.
JOURNAL OF MEDICINAL CHEMISTRY (2020)
Design, Synthesis, and Biological Evaluation of Linear Aliphatic Amine-Linked Triaryl Derivatives as Potent Small-Molecule Inhibitors of the Programmed Cell Death-1/Programmed Cell Death-Ligand 1 Interaction with Promising Antitumor Effects In Vivo
Jialin Guo et al.
JOURNAL OF MEDICINAL CHEMISTRY (2020)
Small-Molecule Immuno-Oncology Therapy: Advances, Challenges and New Directions
Shulun Chen et al.
CURRENT TOPICS IN MEDICINAL CHEMISTRY (2019)
Discovery of [1,2,4]Triazolo[4,3-a]pyridines as Potent Inhibitors Targeting the Programmed Cell Death-1/Programmed Cell Death-Ligand 1 Interaction
Mingze Qin et al.
JOURNAL OF MEDICINAL CHEMISTRY (2019)
Development of the Inhibitors That Target the PD-1/PD-L1 InteractionA Brief Look at Progress on Small Molecules, Peptides and Macrocycles
Katarzyna Guzik et al.
MOLECULES (2019)
Symmetry-based ligand design and evaluation of small molecule inhibitors of programmed cell death-1/programmed death-ligand 1 interaction
Seiji Kawashita et al.
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS (2019)
Design, Synthesis, Evaluation, and Structural Studies of C2-Symmetric Small Molecule Inhibitors of Programmed Cell Death1/Programmed Death-Ligand 1 Protein-Protein Interaction
Subhadwip Basu et al.
JOURNAL OF MEDICINAL CHEMISTRY (2019)
Immune checkpoint inhibitors of PD-L1 as cancer therapeutics
Akintunde Akinleye et al.
JOURNAL OF HEMATOLOGY & ONCOLOGY (2019)
Melanoma-Derived Exosomes Induce PD-1 Overexpression and Tumor Progression via Mesenchymal Stem Cell Oncogenic Reprogramming
Edina Gyukity-Sebestyen et al.
FRONTIERS IN IMMUNOLOGY (2019)
Peptide-based and small synthetic molecule inhibitors on PD-1/PD-L1 pathway: A new choice for immunotherapy?
Tingkai Chen et al.
EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY (2019)
Small Molecules Drive Big Improvements in Immuno-Oncology Therapies
Bayard R. Huck et al.
ANGEWANDTE CHEMIE-INTERNATIONAL EDITION (2018)
Lessons learned from the blockade of immune checkpoints in cancer immunotherapy
Xiaolei Li et al.
JOURNAL OF HEMATOLOGY & ONCOLOGY (2018)
Structure-Function Analysis of Immune Checkpoint Receptors to Guide Emerging Anticancer Immunotherapy
Rita C. Acurcio et al.
JOURNAL OF MEDICINAL CHEMISTRY (2018)
Regulation of PD-L1: Emerging Routes for Targeting Tumor Immune Evasion
Yiting Wang et al.
FRONTIERS IN PHARMACOLOGY (2018)
Safety of resuming anti-PD-1 in patients with immune-related adverse events (irAEs) during combined anti-CTLA-4 and anti-PD1 in metastatic melanoma
M. H. Pollack et al.
ANNALS OF ONCOLOGY (2018)
Circulating and disseminated tumour cells - mechanisms of immune surveillance and escape
Malte Mohme et al.
NATURE REVIEWS CLINICAL ONCOLOGY (2017)
Systematic study of imidazoles inhibiting IDO1 via the integration of molecular mechanics and quantum mechanics calculations
Yi Zou et al.
EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY (2017)
Clinical Pharmacology Considerations for the Development of Immune Checkpoint Inhibitors
Jennifer Sheng et al.
JOURNAL OF CLINICAL PHARMACOLOGY (2017)
Inflammatory CNS disease caused by immune checkpoint inhibitors: status and perspectives
Lidia M. Yshii et al.
NATURE REVIEWS NEUROLOGY (2017)
Small-molecule inhibitors of PD-1/PD-L1 immune checkpoint alleviate the PD-L1-induced exhaustion of T-cells
Lukasz Skalniak et al.
ONCOTARGET (2017)
PD-L1 overexpression is partially regulated by EGFR/HER2 signaling and associated with poor prognosis in patients with non-small-cell lung cancer
Riki Okita et al.
CANCER IMMUNOLOGY IMMUNOTHERAPY (2017)
Coinhibitory Pathways in the B7-CD28 Ligand-Receptor Family
Frank A. Schildberg et al.
IMMUNITY (2016)
Tumor CTLA-4 overexpression predicts poor survival in patients with nasopharyngeal carcinoma
Pei-Yu Huang et al.
ONCOTARGET (2016)
Immune Checkpoint Modulators: An Emerging Antiglioma Armamentarium
Eileen S. Kim et al.
JOURNAL OF IMMUNOLOGY RESEARCH (2016)
Immune Checkpoint Blockade: A Common Denominator Approach to Cancer Therapy
Suzanne L. Topalian et al.
CANCER CELL (2015)
Combination cancer immunotherapy and new immunomodulatory targets
Kathleen M. Mahoney et al.
NATURE REVIEWS DRUG DISCOVERY (2015)
The future of immune checkpoint therapy
Padmanee Sharma et al.
SCIENCE (2015)
The cellular thermal shift assay for evaluating drug target interactions in cells
Rozbeh Jafari et al.
NATURE PROTOCOLS (2014)
Molecular mechanisms of T cell co-stimulation and co-inhibition
Lieping Chen et al.
NATURE REVIEWS IMMUNOLOGY (2013)
MMPBSA.py: An Efficient Program for End-State Free Energy Calculations
Bill R. Miller et al.
JOURNAL OF CHEMICAL THEORY AND COMPUTATION (2012)
The blockade of immune checkpoints in cancer immunotherapy
Drew M. Pardoll
NATURE REVIEWS CANCER (2012)
Share Paper
